Skip to main content
. 2019 Feb 1;10(10):1070–1084. doi: 10.18632/oncotarget.26626

Table 7. Patients with BRAF V600E mutation.

Sex Age Location Antibody DpR (%) PFS (months) OS (months)
Case 1 F 54 Left Cmab -38 5.1 10.0
Case 2 F 64 Right Bmab 7 8.2 12.9
Case 3 F 52 Right Bmab -24 10.3 25.2

Abbreviations: F, female; Cmab, cetuximab; Bmab, bevacizumab; DpR, depth of response; PFS, progression free survival; OS, overall survival.